Invivyd announced that PEMGARDA (pemivibart) demonstrates continued neutralizing activity against dominant SARS-CoV-2 variants KP.3.1.1 and LB.1 in new pseudovirus in vitro tests. KP.3.1.1 currently accounts for 42.2% of circulating variants and is the only major variant showing increasing prevalence nationally, according to CDC data from late August.The tested variants, including those with key mutations Q493E and S31 deletion, remain susceptible to pemivibart. As of September 2024, the primary structure of the pemivibart epitope has maintained integrity across 99.59% of viral sequences in GISAID since Omicron BA.1. Pemivibart has now shown antiviral activity against 33 distinct SARS-CoV-2 variants over two years.The company has submitted these new efficacy data to FDA for updates to the PEMGARDA Fact Sheet. Additionally, their pipeline candidate VYD2311 demonstrated strong neutralization potency against the same contemporary viruses, highlighting Invivyd's continued progress in developing variation-resistant COVID-19 antibody medicines.

Invivyd announced that PEMGARDA (pemivibart) demonstrates continued neutralizing activity against dominant SARS-CoV-2 variants KP.3.1.1 and LB.1 in new pseudovirus in vitro tests. KP.3.1.1 currently accounts for 42.2% of circulating variants and is the only major variant showing increasing prevalence nationally, according to CDC data from late August.The tested variants, including those with key mutations Q493E and S31 deletion, remain susceptible to pemivibart. As of September 2024, the primary structure of the pemivibart epitope has maintained integrity across 99.59% of viral sequences in GISAID since Omicron BA.1. Pemivibart has now shown antiviral activity against 33 distinct SARS-CoV-2 variants over two years.The company has submitted these new efficacy data to FDA for updates to the PEMGARDA Fact Sheet. Additionally, their pipeline candidate VYD2311 demonstrated strong neutralization potency against the same contemporary viruses, highlighting Invivyd's continued progress in developing variation-resistant COVID-19 antibody medicines.